Leverage biotechs for pipeline boost with reduced risk. Navigate the large ecosystem to select assets fitting your strategy for successful partnerships.| Evaluate
Andrew Ward discusses the role of analogs in pharmaceutical forecasting and shares best practices their successful use in this short video.| Evaluate
Discover how pharma and biotech are converging in a consumer-driven landscape. Learn about direct-to-patient models, carve-out deals, and why some biotechs are going solo. Get early access to insights from “Pharma v Biotech: New Rules?” and stay ahead of the curve.| Evaluate
Discover how biotech and Big Pharma are evolving under pressure. From China’s R&D surge to pricing reform, we reveal key market shifts that are reshaping the pharma landscape.| Evaluate
Learn how to improve pharmaceutical sales forecasting accuracy. Discover methods, data sources, and eventing techniques to create reliable sales forecasts in pharma.| Evaluate
Discover how a configurable treatment value model empowers pharmaceutical companies, healthcare professionals, and patients in emerging therapeutic markets—enhancing drug launch strategies, treatment access, and clinical decision-making with real-world data and cost transparency.| Evaluate
Andrew Ward discusses the continued relevance of Excel-based forecasting as part of a forecasters software toolkit, highlighting its flexibility, transparency, and universal accessibility.| Evaluate
The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate